Nanomedicine News RSS Feed - Nanomedicine

Processing Can Affect Drug Nanocarriers Produced From Self-Assembled Polymers

Processing Can Affect Drug Nanocarriers Produced From Self-Assembled Polymers

Significant advances have been made in chemotherapy over the past decade, but targeting drugs to cancer cells while avoiding healthy tissues continues to be a major challenge. [More]
Merrimack MM-398 Study Demonstrates Feasibility of Ferumoxytol Iron Oxide Nanoparticle as a Tumor Imaging Agent

Merrimack MM-398 Study Demonstrates Feasibility of Ferumoxytol Iron Oxide Nanoparticle as a Tumor Imaging Agent

Merrimack Pharmaceuticals, Inc. today announced Phase 1 results from a clinical pilot study demonstrating that ferumoxytol*, an iron oxide nanoparticle, was well tolerated when used as a tumor contrast agent prior to MM-398 treatment. Data from the first cohort of patients in this study were presented at the American Association of Cancer Research Annual Meeting, April 5-9, 2014, in San Diego, California. [More]
Magnetic Nanoparticle Hyperthermia May Hold Promise for Breast Cancer Treatment

Magnetic Nanoparticle Hyperthermia May Hold Promise for Breast Cancer Treatment

In a presentation exploring the promise of magnetic nanoparticle (mNP) hyperthermia in breast cancer treatment, Dartmouth researcher P. Jack Hoopes, DMV, PhD, reviewed preclinical studies conducted at Norris Cotton Cancer Center and discuss plans for early-phase clinical studies in humans at the annual meeting of the American Association for Cancer Research (AACR). [More]
Clinical Data on BIND Therapeutics’ BIND-014 Nanoparticle Drug Candidate Presented at AACR Meeting

Clinical Data on BIND Therapeutics’ BIND-014 Nanoparticle Drug Candidate Presented at AACR Meeting

BIND Therapeutics, Inc., a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins™, announced today that clinical data on its lead drug candidate, BIND-014, were presented at the American Association of Cancer Research (AACR) meeting. [More]
Sorrento to Present Data on Cynviloq-Abraxane PK Study for Ovarian Cancer

Sorrento to Present Data on Cynviloq-Abraxane PK Study for Ovarian Cancer

Sorrento Therapeutics, Inc. (Sorrento), a late-stage clinical oncology company developing new treatments for cancer and its associated pain, announced today that it will present data on the comparison of Cynviloq™ and Abraxane® (nab-paclitaxel) pharmacokinetics (PK) from animal studies. [More]
Lasers Trigger Nanoballoons to Release Drugs

Lasers Trigger Nanoballoons to Release Drugs

Chemotherapeutic drugs excel at fighting cancer, but they're not so efficient at getting where they need to go. [More]
Controlled Rotation of Magnetic Nanoparticles Could Force Tumour Cells to 'Self-Destruct'

Controlled Rotation of Magnetic Nanoparticles Could Force Tumour Cells to 'Self-Destruct'

Using magnetically controlled nanoparticles to force tumour cells to 'self-destruct' sounds like science fiction, but could be a future part of cancer treatment, according to research from Lund University in Sweden. [More]
Baxter to Acquire Chatham’s Hemophilia Developmental Gene Therapy Programs

Baxter to Acquire Chatham’s Hemophilia Developmental Gene Therapy Programs

Baxter International Inc. and Chatham Therapeutics, LLC, today announced that Baxter has agreed to acquire all of Chatham’s outstanding membership interests. As a result of the transaction, Baxter will acquire Chatham’s developmental gene therapy programs directed toward the development and commercialization of treatments for hemophilia. [More]
Rexahn to Present Poster on RX-21101 Nano-Polymer-Drug Conjugate Systems at AACR Meeting

Rexahn to Present Poster on RX-21101 Nano-Polymer-Drug Conjugate Systems at AACR Meeting

Rexahn Pharmaceuticals, Inc. a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, today announced that it will have two poster presentations at the 2014 American Association for Cancer Research (AACR) Annual Meeting. The conference will take place in San Diego, California, on April 5-9, 2014 at the San Diego Convention Center. [More]
Tekmira Reports Positive Results of LNP Technology at Symposium of Filoviruses

Tekmira Reports Positive Results of LNP Technology at Symposium of Filoviruses

Tekmira Pharmaceuticals Corporation, a leading developer of RNA interference (RNAi) therapeutics, announced that recent advances in its anti-viral product platform were presented at the 6th International Symposium of Filoviruses, which is taking place in Galveston, Texas from March 30 to April 2, 2014. [More]
Site Sponsors
  • Park Systems - Manufacturer of a complete range of AFM solutions
  • Oxford Instruments Nanoanalysis - X-Max Large Area Analytical EDS SDD
  • 20% off Mass Spectrometer range at Conquer Scientific
  • Strem Chemicals - Nanomaterials for R&D
  • Technical Sales Solutions - 5% off any SEM, TEM, FIB or Dual Beam